Independent analysis for European life sciences leaders
Life Sciences Commercial Transformation in Europe
disrupting.healthcare examines the commercial shifts reshaping pharma, MedTech and digital health in Europe: operating models, AI, regulation, market access, evidence and execution.
European Life Sciences Commercial Transformation: What H1 2026 Actually Changed
H1 2026 SYNTHESIS · 13-MINUTE READ The product did not become less important. It became less sufficient. The first half of 2026 did not make the molecule, device or algorithm…
Written by Piotr Wrzosinski, a life sciences commercial transformation leader with 20+ years across BD, Roche, Janssen/J&J, Pfizer, Accenture and IQVIA. At BD, he is building EMEA commercial transformation infrastructure across 30+ markets.
Start here
Three analyses that define the publication
Commercial transformation, digital health scale and European market intelligence—viewed through the decisions operators actually have to make.
01 · Commercial operating models
AI-Powered Commercial Operating Models in Life Sciences
AI adoption is not operating-model redesign. Decision rights, data, governance and roles must change before commercial AI can scale beyond disconnected pilots.
02 · Commercialisation
Digital Health Commercialisation in Europe
Regulatory access is only permission to compete. Integration, evidence, adoption and reimbursement determine who scales.
03 · Market intelligence
European HealthTech Market Map 2026
A sourced view of the companies, funding signals and business models shaping European digital health and life-sciences infrastructure.
The Weekly Signal
What matters in European life sciences
A weekly editorial briefing on the regulatory, commercial, scientific and capital-market moves reshaping pharma, MedTech and digital health in Europe.
Primary sources wherever available. Analysis separated from reported fact. Written for operators, not spectators.
Europe Life Sciences Weekly Signal #51: The Price of Time-to-Market
WEEK OF 17-23 AUGUST 2026 · 12-MINUTE READ The most expensive commodity in European life sciences this week was not…
Explore the publication
Three lenses on how innovation works in Europe
01
Commercialization
Operating models, go-to-market choices and the realities of cross-market execution.
03
Regulation & Market Access
Evidence, reimbursement and the rules determining whether innovation reaches patients.
Independent analysis. No sponsored placements. Sources linked.